Literature DB >> 18285461

A role for interferon regulatory factor 4 in receptor editing.

Simanta Pathak1, Shibin Ma, Long Trinh, Runqing Lu.   

Abstract

Receptor editing is the primary means through which B cells revise antigen receptors and maintain central tolerance. Previous studies have demonstrated that interferon regulatory factor 4 (IRF-4) and IRF-8 promote immunoglobulin light-chain rearrangement and transcription at the pre-B stage. Here, the roles of IRF-4 and -8 in receptor editing were analyzed. Our results show that secondary rearrangement was impaired in IRF-4 but not IRF-8 mutant mice, suggesting that receptor editing is defective in the absence of IRF-4. The role of IRF-4 in receptor editing was further examined in B-cell-receptor (BCR) transgenic mice. Our results show that secondary rearrangement triggered by membrane-bound antigen was defective in the IRF-4-deficient mice. Our results further reveal that the defect in secondary rearrangement is more severe at the immunoglobulin lambda locus than at the kappa locus, indicating that IRF-4 is more critical for the lambda rearrangement. We provide evidence demonstrating that the expression of IRF-4 in immature B cells is rapidly induced by self-antigen and that the reconstitution of IRF-4 expression in the IRF-4 mutant immature B cells promotes secondary rearrangement. Thus, our studies identify IRF-4 as a nuclear effector of a BCR signaling pathway that promotes secondary rearrangement at the immature B-cell stage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285461      PMCID: PMC2293099          DOI: 10.1128/MCB.01946-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens.

Authors:  S B Hartley; J Crosbie; R Brink; A B Kantor; A Basten; C C Goodnow
Journal:  Nature       Date:  1991-10-24       Impact factor: 49.962

3.  Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1.

Authors:  A L Brass; E Kehrli; C F Eisenbeis; U Storb; H Singh
Journal:  Genes Dev       Date:  1996-09-15       Impact factor: 11.361

Review 4.  The cell cycle and V(D)J recombination.

Authors:  S Desiderio; W C Lin; Z Li
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

5.  Activation of immunoglobulin kappa gene rearrangement correlates with induction of germline kappa gene transcription.

Authors:  M S Schlissel; D Baltimore
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

6.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

7.  Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains.

Authors:  S Nagulapalli; M L Atchison
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

8.  Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells.

Authors:  J Lang; B Arnold; G Hammerling; A W Harris; S Korsmeyer; D Russell; A Strasser; D Nemazee
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

9.  Receptor editing occurs frequently during normal B cell development.

Authors:  M W Retter; D Nemazee
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

10.  Receptor editing: an approach by autoreactive B cells to escape tolerance.

Authors:  D Gay; T Saunders; S Camper; M Weigert
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  13 in total

1.  Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression.

Authors:  Shibin Ma; Simanta Pathak; Malay Mandal; Long Trinh; Marcus R Clark; Runqing Lu
Journal:  Mol Cell Biol       Date:  2010-06-21       Impact factor: 4.272

2.  Critical role of IRF-5 in regulation of B-cell differentiation.

Authors:  Chunyang Lien; Chee-Mun Fang; David Huso; Ferenc Livak; Runqing Lu; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

3.  VprBP Is Required for Efficient Editing and Selection of Igκ+ B Cells, but Is Dispensable for Igλ+ and Marginal Zone B Cell Maturation and Selection.

Authors:  Victoria L Palmer; Razia Aziz-Seible; Michele D Kassmeier; Mary Rothermund; Greg A Perry; Patrick C Swanson
Journal:  J Immunol       Date:  2015-07-06       Impact factor: 5.422

4.  Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells.

Authors:  Adriana Forero; Kevin D McCormick; Frank J Jenkins; Saumendra N Sarkar
Journal:  Virology       Date:  2014-05-05       Impact factor: 3.616

Review 5.  Mechanisms of central tolerance for B cells.

Authors:  David Nemazee
Journal:  Nat Rev Immunol       Date:  2017-04-03       Impact factor: 53.106

6.  No evidence for a genetic association of IRF4 with systemic lupus erythematosus in a Chinese population.

Authors:  S-S Liu; D Ye; J Lou; Z Fan; D-Q Ye
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

7.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113

Review 8.  IRF4: Immunity. Malignancy! Therapy?

Authors:  Arthur L Shaffer; N C Tolga Emre; Paul B Romesser; Louis M Staudt
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

Review 9.  Interferon regulatory factor 4 and 8 in B-cell development.

Authors:  Runqing Lu
Journal:  Trends Immunol       Date:  2008-09-03       Impact factor: 16.687

10.  NF-kappaB activity marks cells engaged in receptor editing.

Authors:  Emily J Cadera; Fengyi Wan; Rupesh H Amin; Hector Nolla; Michael J Lenardo; Mark S Schlissel
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.